Skip to main content
2026 Prospectus
American Pharmacists Month 2026 executive healthcare observance hero.

· Executive Brief

American Pharmacists Month 2026

Recognize the people while reviewing the operating conditions that help them contribute safely and effectively.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 30 min read

Leadership signal

Recognition becomes useful when leaders inspect the real route.

A workforce observance gives leaders a defined point to compare formal role expectations with the work people actually perform. The review can surface invisible coordination, inconsistent escalation, avoidable rework, and tools that require staff to compensate for system gaps.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

Pharmacists sit on the enterprise’s medication risk, and the operating model decides how much of it they can reduce

American Pharmacists Month is usually framed as recognition. For a health-system executive, it is also a useful moment to ask a harder operating question. Where does medication risk concentrate across the enterprise, and is the pharmacist workforce positioned, staffed and measured to reduce it? The answer rarely sits in one department. It runs through emergency intake, inpatient units, discharge, ambulatory clinics, retail and specialty pharmacy, and the community pharmacies that patients rely on after they leave.

The published evidence is more specific than general praise. Pharmacist care for outpatients with hypertension lowered systolic blood pressure by 5.3 mmHg across 95 randomized trials.[7] Pharmacist-led reconciliation in routine hospital practice was linked to clinically important discharge medication errors in 9.3% of patients, compared with 61.9% on control wards.[13] At the same time, a large U.S. randomized trial of pharmacist-led discharge care did not reduce overall 30-day unplanned hospital or emergency department use among older adults with polypharmacy.[4] Leaders need both findings in view: the role reliably improves medication accuracy, while utilization effects depend on who is targeted and what happens after discharge.

Access is the other half of the picture. Of 88,930 U.S. retail pharmacies operating during 2010 to 2020, 29.4 percent had closed by 2021, with higher closure risk in predominantly Black and Latinx neighborhoods.[9] And the workforce delivering this care reports burnout at levels that should concern any board.[6][12]

This section of the brief adds the evidence base behind the executive guidance that follows. It is written so that leaders can separate what the studies show from the management choices that remain local. Where a sentence carries a citation, the fact comes from the cited study. Where it does not, it is executive guidance for local adaptation, and it should be tested against the organization’s own data, staffing and patient population before it shapes a budget or a board commitment.

Current evidence

What the studies show about pharmacist-led care, and where the effect stops

The clearest signal is in chronic disease management. A meta-analysis of 95 randomized controlled trials with 31,168 participants found that pharmacist interventions for outpatients with hypertension reduced systolic blood pressure by 5.3 mmHg and diastolic blood pressure by 2.3 mmHg.[7] The systolic effect tended to be larger when interventions were collaborative, delivered in outpatient clinics, or included education or feedback to other clinicians.[7] For executives, that pattern matters more than the headline number: the benefit appears strongest when pharmacists work inside the care team rather than beside it.

Medication accuracy at the front door is a second, well-documented contribution. In a prospective study of 161 emergency department patients at a university hospital in Alexandria, clinical pharmacists produced an accurate drug history in 75.16% of revised profiles, compared with 50.3% for physicians.[14] The team identified 585 medication discrepancies, an average of 3.63 per medication sheet, and the number of discrepancies rose with comorbidities and the number of pre-admission medications.[14] The patients most exposed to reconciliation error are the same complex patients who drive readmission risk.

The discharge evidence is more nuanced. In a pragmatic controlled trial of 414 general medical patients at a Slovenian teaching hospital, clinically important discharge medication errors were 9.3% with routine pharmacist-led reconciliation versus 61.9% in controls.[13] Unplanned healthcare use within 30 days did not differ significantly.[13] The authors described reconciliation as fundamental but insufficient for post-discharge safety.[13]

The largest U.S. test points in the same direction. A randomized trial at two urban teaching hospitals enrolled adults aged 55 or older taking 10 or more long-term medications or 3 or more high-risk medications.[4] In the per-protocol Medicare fee-for-service analysis, unplanned 30-day all-hospital use was 26.4% with usual care and 25.6% with the intervention, a difference that was not significant.[4] Among 589 patients with low medication adherence and literacy, however, same-hospital unplanned use fell from 28.8% to 18.3%.[4] The investigators also noted that hospitals rarely have a direct financial incentive to fund these services.[4]

Taken together, the evidence supports pharmacist roles as a medication-accuracy and chronic-disease control asset, while cautioning against promising enterprise-wide readmission savings without targeting. A business case built on blanket utilization reductions is likely to disappoint. A case built on medication accuracy, chronic disease control and focused transition support for the highest-risk patients is better aligned with what the trials actually report, and easier to verify once the service is running.

Figure 1

Pharmacist-led transition care: errors fall sharply, utilization barely moves

Pharmacist-led transition care: errors fall sharply, utilization barely movesPercent of patients with the stated outcome, as reported in each trial abstract. Values are copied from the cited studies [4], [13]; none is estimated.0%25%50%75%100%Clinically important dischargemedication errors, controlClinically important discharge medication errors, control: 61.9% (source [13])61.9%[13]Clinically important dischargemedication errors, pharmacistClinically important discharge medication errors, pharmacist reconciliation: 9.3% (source [13])9.3%[13]Unplanned 30-day all-hospital use, usualcareUnplanned 30-day all-hospital use, usual care: 26.4% (source [4])26.4%[4]Unplanned 30-day all-hospital use,pharmacist-led discharge careUnplanned 30-day all-hospital use, pharmacist-led discharge care: 25.6% (source [4])25.6%[4]Same-hospital unplanned 30-day use,usual care, low adherence and literacySame-hospital unplanned 30-day use, usual care, low adherence and literacy subgroup: 28.8% (source [4])28.8%[4]Same-hospital unplanned 30-day use,intervention, low adherence and literacySame-hospital unplanned 30-day use, intervention, low adherence and literacy subgroup: 18.3% (source [4])18.3%[4]Source [13]Source [4]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of patients with the stated outcome, as reported in each trial abstract. Values are copied from the cited studies [4], [13]; none is estimated.

Data note. Error bars and utilization bars measure different outcomes in different populations and come from two separate trials, so this is an indirect comparison; compare only within each pair.

Limitation. The Slovenian trial was controlled but not individually randomized; the U.S. subgroup result needs confirmation and the all-hospital outcome is limited to fee-for-service Medicare patients.

Figure data (6 rows)
Figure 1 data: Pharmacist-led transition care: errors fall sharply, utilization barely moves
MeasureValuePopulation, setting and year as reportedSource
Clinically important discharge medication errors, control61.9%Adult general medical patients, teaching hospital in Slovenia, pragmatic controlled trial (n=414); control wards[13]
Clinically important discharge medication errors, pharmacist reconciliation9.3%Same trial; intervention ward with admission and discharge reconciliation plus counseling[13]
Unplanned 30-day all-hospital use, usual care26.4%Adults 55+ with polypharmacy or high-risk medications, 2 U.S. urban teaching hospitals, per-protocol fee-for-service Medicare group (593 of 2,242)[4]
Unplanned 30-day all-hospital use, pharmacist-led discharge care25.6%Same trial and group (570 of 2,230); difference not significant[4]
Same-hospital unplanned 30-day use, usual care, low adherence and literacy subgroup28.8%Same trial; subgroup of 589 patients (69 of 240)[4]
Same-hospital unplanned 30-day use, intervention, low adherence and literacy subgroup18.3%Same trial; subgroup (64 of 349)[4]
A pharmacy technician scans a prescription vial at the verification station.
Illustrative image. Pharmacist-led reconciliation in routine hospital practice reduced clinically important discharge medication errors from 61.9% to 9.3% of patients.[13]

Continuum of care

Medication risk moves with the patient, and so must ownership

Medication safety fails most often at the seams between settings, which is why reconciliation is a continuum problem rather than a single pharmacy task. The emergency department study found an average of 3.63 discrepancies per medication sheet, and 33.5% of them fell in categories D, E and F of the error index the authors used.[14] Errors that enter the record at admission can travel through the stay and into the discharge list if no one owns verification.

Discharge is the next point of exposure. The Slovenian trial showed that structured admission and discharge reconciliation, plus patient counseling, can sharply reduce clinically important errors in the discharge list.[13] Yet the same study found serious unplanned healthcare use rose with patient age, number of admission medications and acute admission, factors the intervention did not neutralize.[13] A clean list at discharge is necessary, but the risk that remains sits in the weeks after the patient leaves.

The U.S. trial tested a more extensive model, in which pharmacists managed medications before and after discharge with patients and their care partners, including medication review, discharge reconciliation and attention to adherence and safety.[4] The overall null result on 30-day utilization, alongside a reduction in the low-adherence, low-literacy subgroup, suggests benefit for patients least able to manage complex regimens alone.[4]

Primary care integration is where the continuum can close. In a qualitative study of hospital pharmacists working in three community health centers in Shenzhen, pharmacists mainly conducted medication reviews and consultations and occasionally made home visits with general practitioners.[8] Informants cited colocation, administrative leadership and incentive systems as facilitators, and general practitioner resistance and insufficient technological support as barriers.[8] Different health system, same lesson: the handoff from hospital to community depends on structure, not goodwill.

For leaders, the operating question is whether the organization can name who verifies the medication list at each transition. It is also whether the community pharmacist and primary care team receive what they need to continue the work. Where the answer is unclear, the gap is usually visible in the record: a reconciled list that never reached the outpatient prescriber, or a follow-up call that no role was scheduled to make.

Figure 3

Why the pathway breaks

Cause-and-effect diagram: Medication errors and unresolved medication problems persist after a patient moves between care settingsUnranked qualitative cause-and-effect diagram for the outcome in the box: Medication errors and unresolved medication problems persist after a patient moves between care settings Causes are assembled from the cited literature [1], [2], [4], [5], [6], [8], [9], [11], [12], [13], [14]; categories are not weighted and their order carries no meaning.Medication errors andunresolved medication problemspersist after a patient movesbetween care settingsPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Pharmacist emotional exhaustion and burnout driven by workload and hours
  • Prescribers unaware of best practice for non-English instructions
  • Limited pharmacist competency training for team-based primary care roles

Process

  • Medication histories taken without pharmacist verification at admission
  • Discharge reconciliation not followed by post-discharge management
  • Transition services spread across all patients instead of those with low adherence and literacy

Technology

  • Insufficient technological support for pharmacists in primary care
  • Discrepancies multiply with the number of pre-admission medications

Environment

  • Retail pharmacy closures, highest in Black and Latinx neighborhoods
  • Fewer pharmacies per resident in minoritized and diverse block groups
  • Sales and throughput pressure in community pharmacy

Policy

  • Hospitals rarely have a direct financial incentive to fund pharmacist transition services
  • Reimbursement and network exclusion raise closure risk for independent pharmacies
  • Unclear ownership of the written instruction between prescriber and pharmacy

Measurement

  • Clinical pharmacy indicators mostly process measures
  • No validated benchmarks for pharmacist services
  • Burnout measured but interventions untested

Unranked qualitative cause-and-effect diagram for the outcome in the box: Medication errors and unresolved medication problems persist after a patient moves between care settings Causes are assembled from the cited literature [1], [2], [4], [5], [6], [8], [9], [11], [12], [13], [14]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeoplePharmacist emotional exhaustion and burnout driven by workload and hours; Prescribers unaware of best practice for non-English instructions; Limited pharmacist competency training for team-based primary care roles
ProcessMedication histories taken without pharmacist verification at admission; Discharge reconciliation not followed by post-discharge management; Transition services spread across all patients instead of those with low adherence and literacy
TechnologyInsufficient technological support for pharmacists in primary care; Discrepancies multiply with the number of pre-admission medications
EnvironmentRetail pharmacy closures, highest in Black and Latinx neighborhoods; Fewer pharmacies per resident in minoritized and diverse block groups; Sales and throughput pressure in community pharmacy
PolicyHospitals rarely have a direct financial incentive to fund pharmacist transition services; Reimbursement and network exclusion raise closure risk for independent pharmacies; Unclear ownership of the written instruction between prescriber and pharmacy
MeasurementClinical pharmacy indicators mostly process measures; No validated benchmarks for pharmacist services; Burnout measured but interventions untested

Access

Pharmacy access is shrinking unevenly, and health systems inherit the gap

Community pharmacy is often the most frequent point of contact a patient has with the health system, and that access is eroding. A national study of all U.S. retail pharmacies found that 29.4 percent of the 88,930 pharmacies operating during 2010 to 2020 had closed by 2021.[9] Independent pharmacies had greater closure risk than chains across all neighborhood and market characteristics.[9] The authors pointed to network participation and public insurance reimbursement as levers for the pharmacies most at risk.[9]

Closures change where patients go, not whether they need medications. A 2026 cross-sectional study of mobile phone mobility data from 112,655 urban census block groups in 45 states and Washington, DC, compared prepandemic and postpandemic periods.[1] Devices from areas with fewer pharmacies were more likely to visit pharmacies in racially or ethnically diverse areas, which suggests that residents travel outside their own neighborhoods to fill the gap.[1] For a health system, those trips are a hidden access cost borne by patients and caregivers, and a likely source of delayed fills and missed doses after discharge.

Rural communities show the other side of access: the pharmacist as the nearest clinician. In a survey of 86 rural community pharmacists after the first U.S. COVID-19 vaccine rollout, almost 85% said they would administer COVID-19 vaccines and more than 75% supported recommending them to eligible patients.[10] Most saw benefits in offering the service, including 74.1% who expected stronger ties with local clinics and public health agencies.[10] The authors framed community pharmacists as among the most accessible health professionals in rural areas.[10]

Prevention capacity follows the same logic. The hypertension meta-analysis found benefit across settings and intervention types, which means pharmacist-delivered blood pressure care is not limited to academic clinics.[7] Executives evaluating service-line strategy can treat pharmacist access points, owned or partnered, as part of the prevention network rather than only as a dispensing channel.

The governance implication is straightforward: pharmacy access belongs on the community health needs agenda, and discharge planning should account for where patients can realistically fill and pick up medications. Meds-to-beds programs, owned outpatient pharmacies and partnerships with community pharmacies are all local choices, but each should be judged by whether it reaches the neighborhoods where access is thinnest.

Executive guidance · System route

Map the path from first contact to verified follow-through.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. See the work
  2. Clarify the role
  3. Align role and capacity
  4. Strengthen handoffs
  5. Learn with staff

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. See the work

    Map formal responsibilities, actual demand, recurring interruptions, coordination load, and work that arrives through informal channels.

  2. Clarify the role

    Align expectations, training, authority, support, and escalation with organizational policy and locally applicable requirements.

  3. Align role and capacity

    Compare formal expectations with actual demand, tools, dependencies, backup coverage, and escalation across representative shifts and settings.

  4. Strengthen handoffs

    Define what the role sends, receives, acknowledges, escalates, and documents when work crosses a boundary.

  5. Learn with staff

    Give the professionals closest to the work a regular voice in reviewing friction, testing changes, and confirming results.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.See the workClarify the roleAlign role andcapacityStrengthenhandoffsLearn with staffLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
See the workMap formal responsibilities, actual demand, recurring interruptions, coordination load, and work that arrives through informal channels.
Clarify the roleAlign expectations, training, authority, support, and escalation with organizational policy and locally applicable requirements.
Align role and capacityCompare formal expectations with actual demand, tools, dependencies, backup coverage, and escalation across representative shifts and settings.
Strengthen handoffsDefine what the role sends, receives, acknowledges, escalates, and documents when work crosses a boundary.
Learn with staffGive the professionals closest to the work a regular voice in reviewing friction, testing changes, and confirming results.

Equity and trust

Pharmacy deserts and language barriers follow segregated lines

Pharmacy access is not distributed evenly. In the national closure study, the risk of closure was higher for pharmacies in predominantly Black and Latinx neighborhoods than in predominantly White neighborhoods.[9] In the 2026 mobility study, minoritized and diverse census block groups had lower odds of having at least one pharmacy, both before and after the pandemic.[1] Predominantly White block groups had 15% more pharmacies per 10,000 people than predominantly minoritized ones.[1] The authors concluded that pharmacy closures and deserts continue to occur disproportionately in communities with predominantly Black and Latinx populations.[1]

Language is a second equity fault line, and it sits partly inside the health system’s own clinics. In a survey of outpatient prescribers at a large U.S. academic medical center, 61.5% reported lacking awareness of best practices for providing non-English prescription instructions.[2] Of the same respondents, 91.8% did not tell patients they could request a non-English medication label from their pharmacy, and 69.8% were not confident that patients with a non-English language preference received accurate written instructions.[2] The authors found prescribers were confused about the dispensing pharmacy’s role.[2]

That finding matters for operations because it describes a handoff failure, not an individual one. Prescribers, interpreters and pharmacies each hold part of the instruction pathway, and no one may own the final written instruction the patient takes home.[2] A language access plan that stops at the clinic door leaves the medication label, often the document a patient consults most, outside its scope.

Literacy and adherence create a related risk. In the U.S. discharge trial, the only group with a significant reduction in same-hospital unplanned use was the 589 patients with low medication adherence and literacy, where use fell from 28.8% to 18.3%.[4] The evidence suggests that equity-focused targeting is not only a fairness choice but also where pharmacist time appears most effective.

Trust is built when patients can find a pharmacy, understand the instructions and reach someone who will answer questions. Each of those depends on enterprise decisions about location, language services and staffing. Equity review should therefore look at pharmacy access, instruction language and transition-service enrollment by neighborhood, language preference and payer, using protected and locally approved methods.

A shuttered storefront pharmacy on a street corner beside an empty bus stop.
Illustrative image. Of 88,930 U.S. retail pharmacies operating during 2010 to 2020, 29.4 percent had closed by 2021, with higher closure risk in predominantly Black and Latinx neighborhoods.[9]

Human infrastructure

The pharmacist workforce is under strain, and the evidence on fixes is thin

Recognition rings hollow if the operating conditions are wearing people down. A narrative review found that U.S. community pharmacists faced high burnout, low quality of life and extreme fatigue before the COVID-19 pandemic.[12] It found no research testing interventions to support well-being or reduce burnout.[12] That gap is itself a leadership finding: organizations cannot buy a proven program off the shelf, so they need to measure and test their own changes.

International studies describe the drivers in operational terms. Among 408 community pharmacists in Saudi Arabia, 65.9% had high emotional exhaustion, and pharmacists facing constant sales pressure had 4.23 times higher odds of high emotional exhaustion.[6] In a second Saudi regional study, emotional exhaustion affected 78.2% of respondents, and burnout correlated with heavy workload, extended hours and insufficient compensation.[5] Pharmacists working more than 48 hours per week had higher burnout.[5] These are settings with different labor markets from the United States, but the mechanisms they name, volume pressure, hours and metrics that reward throughput, are familiar to U.S. retail and health-system pharmacy leaders.

Hospital pharmacists are not exempt. In a cross-sectional study of 115 health-system pharmacists in Lebanon, 43.5% met the study’s burnout definition, mostly driven by high emotional exhaustion.[15] Divided attention at work, career dissatisfaction and neutral or dissatisfied views of work-life balance were among the factors associated with higher burnout.[15] Common coping strategies such as holidays and hobbies showed no association with burnout.[15] Personal resilience, in other words, did not offset work design.

Workforce strain also limits role expansion. Hospital pharmacists integrated into Shenzhen primary care cited inadequate competency and lack of patient recognition as barriers, and the authors recommended targeted training in practical pharmacist skills.[8] Moving pharmacists into team-based roles requires protected time and development, not only a new job description.

For executives, the human infrastructure question is whether the pharmacist role has the time, training and interruption control needed to do the medication-safety work the evidence supports. Adding reconciliation, transition calls or hypertension visits to an already saturated verification workload simply moves the risk. Capacity has to be created, through technician support, workflow redesign or staffing, before the new role is announced, and the effect on workload should be checked with the pharmacists themselves after launch.

Executive guidance · Operating dashboard

Measure whether the operating route works as intended.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Role clarityCapacity resilienceRole-capacity alignmentVoice and improvement

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Role clarity

Are expectations, authority, support, and escalation understood by the role and its partners?

Candidate local measure
Locally defined scope questions, misroutes, reassignment, and escalation signals.

Executive guidance · Signal

Capacity resilience

Can the operating model absorb predictable demand and planned absences without unsafe workarounds?

Candidate local measure
Coverage gaps, schedule stability, overtime, backlog, and backup activation under local definitions.

Executive guidance · Signal

Role-capacity alignment

Does the operating model match demand while preserving clear role, support, and escalation?

Candidate local measure
Locally defined workload, backlog, coverage gaps, reassignment, escalation, and staff feedback.

Executive guidance · Signal

Voice and improvement

Can staff raise concerns and help redesign the work with visible follow-through?

Candidate local measure
Improvement ideas, assigned owners, response status, completed changes, and staff feedback.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Role clarityOwner: Executive sponsor andoperational leadCapacity resilienceOwner: Operational owner andparticipating teamsRole-capacity alignmentOwner: Sending and receiving ownersVoice and improvementOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Role clarityExecutive sponsor and operational lead
Capacity resilienceOperational owner and participating teams
Role-capacity alignmentSending and receiving owners
Voice and improvementImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Keep work owned when it crosses a boundary.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. State what the role sends, receives, acknowledges, escalates, and documents at each operating boundary.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Ask questions that connect intent, ownership, and results.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signal Executive question Candidate owner Suggested review point
Role clarity Are expectations, authority, support, and escalation understood by the role and its partners? Executive sponsor and operational lead At campaign launch and close
Capacity resilience Can the operating model absorb predictable demand and planned absences without unsafe workarounds? Operational owner and participating teams At a locally defined cadence
Role-capacity alignment Does the operating model match demand while preserving clear role, support, and escalation? Sending and receiving owners At a locally defined cadence
Voice and improvement Can staff raise concerns and help redesign the work with visible follow-through? Improvement owner and executive sponsor Until action is verified

Figure 5

Medication-transition control points for executive review

Figure 5: Medication-transition control points for executive review
Control pointRisk if missingOwnerEvidence of control
Pharmacist-verified medication history for high-risk admissionsDiscrepancies enter the record and carry through the stayChief pharmacy officer with emergency department leadershipShare of high-risk admissions with pharmacist-verified history, reviewed monthly
Discharge reconciliation with patient counselingClinically important errors on the discharge listInpatient pharmacy and nursing leadershipAudited sample of discharge lists with error rate tracked over time
Targeted post-discharge pharmacist follow-upEffort spread too thin to change outcomes for those at highest riskCare transitions executive sponsorEnrollment of patients flagged for low adherence or literacy, with completed follow-up
Language-accessible written medication instructionsPatients leave with instructions they cannot readLanguage services and pharmacy leadership jointlyRate of non-English labels or instructions provided when a preference is recorded
Pharmacy access review in the service areaDischarge plans assume a pharmacy the patient cannot reachCommunity health and strategy leadershipMapped pharmacy access for priority neighborhoods, updated each planning cycle
Pharmacist workload and well-being monitoringBurnout erodes the capacity for clinical workChief pharmacy officer with human resourcesWorkload, overtime and burnout survey results reviewed with action owners
Outcome-level pharmacy measures for the boardActivity counts are mistaken for impactQuality committee of the boardScorecard pairing process and outcome measures, stratified by population

Control points derived from the cited evidence [2], [4], [9], [11], [12], [13], [14] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Tell patients what pharmacists can do, and measure what they actually deliver

Public communication during American Pharmacists Month can close an awareness gap that patients report directly. In a survey of 4,395 Dutch pharmacy visitors, 48% knew medication reviews existed, while 85% considered them important.[3] Among the 27% who had received a review, 92% felt able to ask questions, 68% reported better medication understanding and 65% reported greater confidence in medication use.[3] Only 62% felt treatment options were sufficiently discussed, and the authors suggested that shared decision-making and follow-up could be better implemented.[3]

Those results point to a simple communication priority: tell patients that pharmacist services exist, how to request them and what they can expect. Language access belongs in the same message, since prescribers in the U.S. academic survey rarely told patients they could ask the pharmacy for a non-English label.[2] Public materials should be accurate about what the organization actually provides and should avoid implying services that are not staffed.

Internal communication with boards needs a stronger measurement base than most organizations have. A systematic review of clinical pharmacy key performance indicators for hospital inpatient settings found 13 studies proposing 225 indicators, of which 85.8% were process measures and only 5.8% were outcome measures.[11] Only 5 studies scored above 50% on the appraisal instrument, the indicators were largely proposed by pharmacists with weak evidence support and no piloting or validation, and none provided benchmarking reference values.[11]

That finding is a caution against reporting activity counts as impact. The trial evidence shows why: reconciliation reduced discharge errors sharply, but did not move overall utilization, and a more extensive discharge model helped mainly in a targeted subgroup.[13][4] Boards should see both process and outcome signals, stratified by the patient groups where the evidence suggests benefit.

Credible communication, internal and external, comes from matching claims to evidence. The observance offers a natural point to publish what pharmacists do, what the organization is measuring and where it is still learning. A short, plain-language statement to patients can explain how to request a medication review, how to ask for instructions in their preferred language and whom to call after discharge. It will do more for trust than general appreciation messaging. For the board, a one-page view that pairs a medication-accuracy measure with an outcome measure, and shows the populations where each is tracked, sets an honest baseline for next year’s observance.

A pharmacist and an older patient review a printed medication list together at a consultation table.
Illustrative image. Across 95 randomized trials, pharmacist care for outpatients with hypertension reduced systolic blood pressure by 5.3 mmHg, with larger effects in collaborative models.[7]

Executive guidance · 90-day plan

Move from listening to a verified improvement in 90 days.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how American Pharmacists Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Ask the professionals closest to the work to select and test one role, tool, workload, or handoff improvement.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how American Pharmacists Month communications connect toreal entry points, owners, transitions, and escalation.Days 1–30: Map how American Pharmacists Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Ask the professionals closest to the work to select and testone role, tool, workload, or handoff improvement.Days 31–60: Ask the professionals closest to the work to select and test one role, tool, workload, or handoff improvement.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how American Pharmacists Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testAsk the professionals closest to the work to select and test one role, tool, workload, or handoff improvement.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Carry one accountable improvement beyond the campaign window.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Listen to the people closest to the route, assign one barrier, and verify the change.

Executive action kit · Month observance

Turn American Pharmacists Month into accountable action.

Recognize the people while reviewing the operating conditions that help them contribute safely and effectively.

Take it with you

Filed under

Nursing and Clinical ProfessionsWorkforce and Organizational HealthMonth

Leadership focus

Use this observance to examine role clarity, capacity, teamwork, and dependable handoffs. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the role, coverage, workload, and escalation pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review whether shift, location, employment status, language, disability, or digital access changes who can use the pathway or receive support.

Five-minute briefing

Inspect the operating sequence

Listen with professionals performing the work, operational leaders, and the teams that depend on them. Find one unclear responsibility, hidden workload, or an unsupported handoff, then test the locally approved route from entry through acknowledged follow-through.

  1. See the work
  2. Clarify the role
  3. Align role and capacity
  4. Strengthen handoffs
  5. Learn with staff
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined scope questions, misroutes, reassignment, and escalation signals.
  • Coverage gaps, schedule stability, overtime, backlog, and backup activation under local definitions.
  • Locally defined workload, backlog, coverage gaps, reassignment, escalation, and staff feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Nursing and Clinical Leaders
  • Workforce and Human Resources Leaders
Staff communication template

During American Pharmacists Month, our organization will connect awareness with a practical review of the role, coverage, workload, and escalation pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

American Pharmacists Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Census Block Group Demographics, Mobility Patterns, and Pharmacy Visits. JAMA Network Open. 2026;9(10):e2637087. https://doi.org/10.1001/jamanetworkopen.2026.37087
  2. 2. Prescriber Practices and Barriers to Providing Prescription Medication Instructions for Patients With a Non-English Language Preference. Annals of Family Medicine. 2026;24(5):447-451. https://doi.org/10.1370/afm.250777
  3. 3. Patients’ perspectives and experiences regarding medication reviews: A cross-sectional survey study. Exploratory Research in Clinical and Social Pharmacy. 2026;21:100692. https://doi.org/10.1016/j.rcsop.2025.100692
  4. 4. Pharmacist-Led Discharge Care to Reduce Postdischarge Health Care Utilization: A Randomized Clinical Trial. JAMA Network Open. 2026;9(3):e260719. https://doi.org/10.1001/jamanetworkopen.2026.0719
  5. 5. Prevalence and risk factors of burnout among community pharmacists in the Aseer region, Saudi Arabia: a cross-sectional study. Frontiers in Pharmacology. 2026;17:1737667. https://doi.org/10.3389/fphar.2026.1737667
  6. 6. Prevalence and risk factors of burnout among community pharmacists in Saudi Arabia: a cross-sectional study. Frontiers in Public Health. 2025;13:1706598. https://doi.org/10.3389/fpubh.2025.1706598
  7. 7. Pharmacists delivering hypertension care services: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine. 2025;12:1477729. https://doi.org/10.3389/fcvm.2025.1477729
  8. 8. The integration of hospital pharmacists into primary care settings in Shenzhen, China: a qualitative study. BMC Health Services Research. 2025;25(1):197. https://doi.org/10.1186/s12913-025-12351-2
  9. 9. More US Pharmacies Closed Than Opened In 2018-21; Independent Pharmacies, Those In Black, Latinx Communities Most At Risk. Health Affairs. 2024;43(12):1703-1711. https://doi.org/10.1377/hlthaff.2024.00192
  10. 10. Rural community pharmacists’ willingness to receive, administer, and recommend COVID-19 vaccines after the First U.S. vaccine rollout. Exploratory Research in Clinical and Social Pharmacy. 2024;16:100520. https://doi.org/10.1016/j.rcsop.2024.100520
  11. 11. Clinical pharmacy key performance indicators for hospital inpatient setting: a systematic review. International Journal of Clinical Pharmacy. 2024;46(3):602-613. https://doi.org/10.1007/s11096-024-01717-x
  12. 12. A narrative review of the well-being and burnout of U.S. community pharmacists. Journal of the American Pharmacists Association. 2024;64(2):337-349. https://doi.org/10.1016/j.japh.2023.11.017
  13. 13. Effectiveness of pharmacist-led medication reconciliation on medication errors at hospital discharge and healthcare utilization in the next 30 days: a pragmatic clinical trial. Frontiers in Pharmacology. 2024;15:1377781. https://doi.org/10.3389/fphar.2024.1377781
  14. 14. The impact of clinical pharmacists’ medication reconciliation upon patients’ admission to reduce medication discrepancies in the emergency department: a prospective quasi-interventional study. International Journal of Emergency Medicine. 2023;16(1):89. https://doi.org/10.1186/s12245-023-00568-z
  15. 15. Burnout and coping strategies among health system pharmacists in Lebanon: a cross-sectional study. BMC Health Services Research. 2023;23(1):424. https://doi.org/10.1186/s12913-023-09422-7

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Pharmacist-delivered hypertension care lowers blood pressure; larger effect in collaborative, clinic-based models[7]2025Current evidenceMeta-analysis with high heterogeneity; many included trials at risk of bias; effects vary by setting and design.
Pharmacist medication histories are more accurate; discrepancies rise with comorbidity and medication count[14]2023Current evidenceSingle-center quasi-interventional study at a university hospital in Alexandria; 161 patients; may not generalize to U.S. emergency departments.
Reconciliation reduces discharge medication errors but not 30-day utilization[13]2024Current evidencePragmatic controlled (not individually randomized) trial at one Slovenian hospital; 414 patients.
Pharmacist-led discharge care did not reduce overall 30-day utilization; benefit in low adherence and literacy subgroup[4]2026Continuum of careTwo U.S. urban teaching hospitals; subgroup finding needs confirmation; all-hospital outcome limited to fee-for-service Medicare claims.
Barriers and facilitators of hospital pharmacist integration into primary care[8]2025Continuum of careQualitative study of 17 informants at three community health centers in Shenzhen, China.
U.S. retail pharmacy closures and higher risk in Black and Latinx neighborhoods and independent pharmacies[9]2024AccessRetail pharmacies only; observational; does not measure patient outcomes of closures.
Fewer pharmacies in minoritized and diverse census block groups; residents travel to other areas[1]2026Equity and trustCross-sectional; urban block groups; mobile device data approximate visits and may not represent all residents.
Rural community pharmacists’ willingness to administer and recommend vaccines[10]2024AccessConvenience sample of 86 pharmacists; 23.4% response rate; COVID-19 vaccines specifically.
Prescriber gaps in non-English prescription instructions and pharmacy label requests[2]2026Equity and trustSingle academic medical center; 35.4% response rate; self-reported practices.
U.S. community pharmacist burnout is measured but interventions are untested[12]2024Human infrastructureNarrative review rather than systematic review; community pharmacy only.
Burnout prevalence and work-design drivers among community and hospital pharmacists[5] [6] [15]2026, 2025, 2023Human infrastructureCross-sectional surveys in Saudi Arabia and Lebanon; labor markets differ from the United States; convenience samples.
Patient awareness and experience of pharmacist medication reviews[3]2026Public communicationOnline panel of Dutch pharmacy visitors; self-reported outcomes; median age 71.
Clinical pharmacy KPIs are mostly process measures with weak validation and no benchmarks[11]2024Public communicationInpatient hospital KPIs only; 13 studies; appraisal instrument scores reflect reporting quality.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.